Table 4.
Type and frequency of the causes of DRP in medicines associated with high risk of DRP in neonatal intensive care
| Medicines | Causes of DRP* | ||||
| Drug selection | Dose selection | Drug use process | Logistics | Others† | |
| Amphotericin B | 7 (15.2%) | 21 (45.7%) | 11 (23.9%) | 7 (15.2%) | |
| Meropenem | 1 (1.0%) | 38 (38.0%) | 25 (25.0%) | 29 (29.0%) | 7 (7.0%) |
| Alprostadil | 2 (12.5%) | 6 (37.5%) | 8 (50.0%) | ||
| Vancomycin | 1 (1.0%) | 28 (28.9%) | 24 (24.74%) | 40 (41.24%) | 4 (4.12%) |
| Ciprofloxacin | 3 (23.08%) | 4 (30.77%) | 2 (15.38%) | 4 (30.77%) | |
| Gentamicin | 132 (62.6%) | 73 (34.6%) | 4 (1.9%) | 2 (0.9%) | |
| Cefepime | 16 (42.1%) | 10 (26.32%) | 11 (28.95%) | 1 (2.63%) | |
| Amikacin | 47 (64.4%) | 14 (19.2%) | 8 (10.9%) | 4 (5.5%) | |
| Omeprazole | 1 (3.57%) | 15 (53.57%) | 12 (42.86%) | ||
*Causes of DRP according to the Pharmaceutical Care Network Europe classification system V.6.2.4
†Others included drug form, treatment duration and other specific causes (eg, adverse reaction and wrong drug preparation technique).
DRP, drug-related problem.